Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

137.08 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have  
Via Benzinga
Why I Sold Kohl’s Corporation Despite Possible Buyout Deal
2022 has been a headline-packed for Kohl’s and KSS stock. But after a closer look at my portfolio grader, this is why it was time to sell. 
Via InvestorPlace
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have  
Via Benzinga
Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks
Via Benzinga
Biogen Says It Cracked The Alzheimer's Puzzle, But Investors May Need More Evidence
Patients who received Aduhelm for over two years showed declines in two markers. 
Via Investor's Business Daily
News-Filled Day
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
Via Talk Markets
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Hopes For A Peace Accord
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
Biogen Posts New Updates Across its Spinraza SMA Research Program
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and... 
Via Benzinga
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
These four medical stocks are outperforming the lousy market for health care investors. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri... 
Via Benzinga
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In... 
Via Benzinga
Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma
Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhelm approval. An analyst at RBC... 
Via Benzinga
Expert Ratings For Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7... 
Via Benzinga
Biogen Has An $8 Billion Alzheimer's Opportunity — Will It Materialize?
A few key things have to go right for Biogen to snag a definitive win in Alzheimer's. 
Via Investor's Business Daily
10 Biggest Price Target Changes For Thursday
Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,... 
Via Benzinga
NASDAQ:BIIB Investor Alert: Lawsuit Alleges Misleading Statements by Biogen Inc.
San Diego, CA -- (SBWIRE) -- 02/23/2022 -- An investor, who purchased NASDAQ:BIIB shares, filed a lawsuit against Biogen Inc over alleged Securities Laws violations. 
Via SBWire
How Many Stocks Are Down From Their Pre-COVID Levels?
On February 19th, 2020, the S&P 500 made its last closing high prior to all hell breaking loose for the next month. 
Via Talk Markets
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
Why A Biogen-Sage Drug Flopped — And Could Still Be Approved
The companies tested a combination of zuranolone and depression drugs. 
Via Investor's Business Daily
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... 
Via Benzinga
US Senate Narrowly Votes In Favor Of Biden's Nominee Robert Califf To Lead FDA For Second Time
By a narrow vote of 50-46, the Senate has confirmed Robert Califf to run the FDA. Califf, who previously served as the FDA commissioner from February 2016 to January... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector. 
Via Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.